Spyre Therapeutics, Inc. granted equity inducement awards to six non-executive employees, comprising 58,843 stock options and 2,134 restricted stock units (RSUs). The awards were approved by the independent Compensation Committee of the Board of Directors on July 1, 2026, and were material to each employee's acceptance of employment with the company. These grants were made under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price of $88.89, which was the closing price per share of Spyre's common stock on Nasdaq on July 1, 2026. Vesting for the options will begin on the first anniversary of the employee’s start date, with one-fourth of the shares becoming exercisable at that time. Thereafter, one-forty-eighth of the shares will vest monthly, subject to continuous service with Spyre through the applicable vesting dates.

The RSUs will vest in quarterly installments, with one-fourth of the shares vesting on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date. This vesting schedule is also contingent upon the employee maintaining continuous service with Spyre through the applicable vesting dates. Both the stock options and RSUs are subject to the terms of the 2018 Plan.

Award Details

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies in immunology. The company's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

Spyre Therapeutics has filed a prospectus for a mixed shelf offering, though the specific terms remain undisclosed. The submission was made to the SEC.

The filing provides a regulatory framework for the company to offer various securities in the future. Details regarding the size of the offering or the types of securities to be issued were not included in the initial document.